SureTrader SureTrader
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: Axeman, otclad
Search This Board:
Last Post: 9/27/2016 6:00:00 PM - Followers: 182 - Board type: Free - Posts Today: 8

RCHA Patent for Treatment of Hodgkin’s Lymphoma

Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma,
RCHA Recent News

Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)

BEVERLY HILLS, Calif., Nov. 23, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich"), with the advice and guidance of Theradex Systems, Inc.,

Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug
(IND) Application For The Treatment of Acute Myelocytic Leukemia

BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014. 
In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. 
Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec. 
We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases. 
Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. 
Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. 

Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:

Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells
(WBC) in patients depleted of these elements due to various conditions.

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. 
Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000.
Based on this incidence,
the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003




Monthly View

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#11359  Sticky Note This is a Share Printing Scam Stock... AVOID makinezmoney 03/11/16 02:37:25 PM
#11844   HOD was 0005!!!!! Back up we go tomorrow OTC Knight 09/27/16 06:00:00 PM
#11843   Added a starter here. News looks good OTC Knight 09/27/16 05:35:43 PM
#11842   Who's he fighting? He's dumping into the news Axeman 09/27/16 01:18:19 PM
#11841   Let's go RCHA!!!! Keep up the fight Ben! Rich540 09/27/16 10:16:12 AM
#11840   This is a longturn play, if you add josemaria 09/27/16 10:04:09 AM
#11839   News Out -- More Ben Fluff: NO MONEY Axeman 09/27/16 09:59:59 AM
#11838   $RCHA News!!! Rider76 09/27/16 09:57:45 AM
#11837   BEN CHANG WILL R/S THIS AGAIN SOON! SCAM onthegreen 09/27/16 09:55:00 AM
#11836   Link Please!!!!!!!!!! stoprun 09/26/16 04:51:34 PM
#11835   When??? Rich540 09/26/16 04:38:37 PM
#11833   "It has been said that the stock markets sunspotter 09/26/16 07:01:27 AM
#11832   It has been said that the stock markets stockscheers 09/22/16 04:36:29 AM
#11831   We've been patient. All we need to know stockscheers 09/19/16 04:22:21 AM
#11830   Incidently, sme time ago I added to what Long-vestor 09/16/16 08:43:47 PM
#11829   LOL Yeap that sounds about right! otclad 09/16/16 07:34:41 PM
#11828   35 billion, divided by 1,000,, and, oh, off Long-vestor 09/16/16 05:05:16 PM
#11827   CHINESE SHARE SELLING SCAM! onthegreen 09/14/16 09:43:41 PM
#11826   What stage is RCHA currently in their development? otclad 09/14/16 07:17:27 AM
#11825   As long as Ben has a good business stockscheers 09/13/16 10:57:23 PM
#11824   More dilution at 2's now... RCHA otclad 09/13/16 10:34:11 AM
#11823   Real money made right before RS.. If otclad 09/11/16 08:09:17 PM
#11822   This will run soon IMO. Rich540 09/11/16 09:35:42 AM
#11821   I am surprised this is not at trip otclad 09/09/16 10:43:21 AM
#11820   Time 4 Ben to R/S again onthegreen 09/08/16 08:46:10 PM
#11819   Ben is doing what he knows best... otclad 09/08/16 03:44:14 PM
#11818   Right. A steady flow of reasonable news releases stockscheers 09/08/16 04:52:11 AM
#11817   Rich Pharmaceuticals and Ben's toxic debt plan will Axeman 09/04/16 09:54:06 PM
#11816   Large drops usually get the attention of bargain stockscheers 09/04/16 09:45:58 PM
#11815   No idea since Ben has not returned my Axeman 09/03/16 07:13:25 PM
#11814   We need an update. How are they doing Rich540 09/03/16 07:11:26 PM
#11813   Oversold but stuck since BEN is constantly Axeman 09/03/16 01:04:57 PM
#11812   RCHA bullish 0.0002 stocktrademan 09/02/16 02:19:47 PM
#11811   I agree. Reverse wouldn't happen for sometime. Just Axeman 08/31/16 03:15:26 PM
#11810   And do you actually think the Company can stoprun 08/31/16 01:29:25 PM
#11809   With no revenue, this is nothing more than otclad 08/31/16 01:01:56 PM
#11808   You are wrong a reverse split with a Axeman 08/29/16 05:07:11 PM
#11807   In my opinion, reverse split is 'no change' stockscheers 08/28/16 11:50:47 PM
#11806   TIME FOR BEN TO REVERSE SPLIT AGAIN!!! onthegreen 08/26/16 12:36:23 PM
#11805   That is true but the CEOs don't help Axeman 08/25/16 08:11:58 PM
#11804   Pink sector is Naked Shorted to death by stoprun 08/25/16 08:09:42 PM
#11803   Boring you know it and I know it Axeman 08/25/16 04:52:50 PM
#11802   I do believe that is the same thing stoprun 08/25/16 04:48:45 PM
#11801   Go read all the filings and get a Axeman 08/25/16 04:21:21 PM
#11800   Link Please, sound familiar, as in GN-P!!!!!!!!!!!!!!! stoprun 08/25/16 04:19:36 PM
#11799   Impossible to say since we are in limbo Axeman 08/25/16 01:35:58 PM
#11798   This seems to be the census, before the otclad 08/25/16 01:29:35 PM
#11797   All I'm trying to do here is get stockscheers 08/25/16 04:40:40 AM
#11796   You need a lot more than news here Axeman 08/24/16 02:17:45 AM
#11795   Iam waiting for news too, but not sure josemaria 08/23/16 02:41:42 PM
#11794   Bring on the good news!!! Rich540 08/23/16 04:11:33 AM